Similarly, the phase II SOLTI-1303 PATRICIA study evaluated the use of palbociclib and trastuzumab, with and without letrozole, in heavily pre-treated patients with HER2-positive advanced breast cancer. Here, ERBB2 is linked to breast carcinoma.